- Glenmark is the first company in India to commercialize the innovative Indacaterol FDC.
- The drug combines two or more active ingredients in a single pill in a fixed dose ratio.
- A long-acting beta-agonist and mometasone furoate, an inhaled corticosteroid that is approved by the DCGI.
Glenmark is the first company in India to commercialize the innovative FDC of Indacaterola beta-agonist of long-acting and mometasone furoatean inhaled corticosteroid that is approved by the DCGI (Drugs Controller General of India).
According to the company’s press release, the company has launched this FDC under the Indamet® brand.
“This is a key focus area for Glenmark and the company is leading from the front in providing access to the latest treatment options for patients. We are proud to introduce this novel Indamet® Fixed Dose Combination, which is the first of its kind in India; offering a world-class, affordable treatment option for adults and adolescents 12 years of age and older suffering from uncontrolled asthma,” said Alok Malik, Group Vice President and Head of India Formulations – Glenmark.
Glenmark is the first company in India to commercialize the innovative FDC of Indacaterol, a long-acting beta-agonist and mometasone furoate, an inhaled corticosteroid that is approved by the DCGI (Drug Controller General of India).
Asthma is one of the main noncommunicable diseases (NCDs) and affects both children and adults. The condition is caused by inflammation and narrowing of the small airways in the lungs.
According to the Global Burden of Disease report of the Institute for Health Metrics and Evaluation (IHME), asthma accounted for 27.9% of disability-adjusted life years (DALYs) in Indians, leading to three times higher mortality and two times higher DALYs compared to the rest of the world. asthma rate.
Related Notes: